Opinion|Videos|July 15, 2024
Financial and Clinical Benefits of RSV Immunization
Following the recent approval of RSV vaccines, the panel discusses the financial and clinical benefits, highlighting the fiscal impact seen in hospitals and ICUs.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- With RSV vaccines newly approved, what are the financial and clinical goals associated with immunizing against RSV?
- Have payers activated early coverage for the adult RSV vaccines since they entered to reduce costs?
- How have RSV vaccines altered the fiscal impact associated with managing RSV infections in hospitals or ICUs?
- How have RSV vaccines altered the fiscal impact associated with managing RSV infections in hospitals or ICUs?
Advertisement
Related to this article
About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.
Advertisement
Advertisement
Trending on AJMC
1
Higher Ropeginterferon Alfa-2b Exposure Liked to JAK2 Reductions in ET
2
Medicare Plan Terminations Hit 4.3 Million as Part D Market Shrinks
3
Menin Inhibitors in AML: In NYC, Experts Map the Path From Academic Centers to Community Care
4
Youths With Depression Face Higher Odds of Prescription Drug Misuse
5